Impella RP Post-Approval Study Data Presented at ACC 2019 Data demonstrates survival benefit with the Impella RP Recover Right protocol The Impella RP FDA post-market study data shows 64% survival ...
Shares in RP Data (pmn.ASX:Quote) began trading at $1.65 at 1130 AEDT on the Australian Stock Exchange, up 40 cents on the $1.25 a share offer price. By 1132 AEDT, the stock had touched a high of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results